Latest Vitrafy Life Sciences (ASX:VFY) News

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Vitrafy Life Sciences announces a leadership change with CEO Kate Munnings retiring and co-founder Brent Owens stepping up to lead the company’s next growth phase.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.